(A) Schematic of treatment plan. The injections were administered as was done for Figure 3. At day 14, the primary tumors and TDLNs were dissected with the complete removal of mammary fat tissue and tumor-overlying skin. At day 18, 4 mice from each group were euthanized for splenocytes restimulation while the others were observed until day 64 for survival analysis. (B) Splenocytes from each group were cultured for 96 hours in the presence of a specific immunodominant peptide expressed by 4T1 cells (gp70_423–431). Enzyme-linked immunosorbent assay was performed for quantification of IFN-γ secreted by the splenocytes (n = 4 per group). (C) Whole body in vivo bioluminescence imaging of 4T1-Luc cells in mice after surgery (n = 6 per group). (D) Kaplan-Meier survival curves of mice (n = 9–11 per group). (E) Tumor growth curve after tumor rechallenge. For tumor rechallenge, 1 × 10⁴ 4T1-Luc cells were inoculated in the contralateral mammary fat pad of mice that survived for 50 days in the mcMEDI/MEDI group or naive mice of similar age. Data are representative of 2 independent experiments for A–D. The experiment for E was performed once. Data presented as mean ± SEM. **P < 0.01; 1-way ANOVA and Tukey’s multiple comparisons test for B, log-rank (Mantel-cox) test for D.